The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2018 | Current landscape and future directions for lower-risk MDS treatment
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX, David Steensma, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the current treatment landscape for lower-risk myelodysplastic syndromes (MDS), as well as future directions for therapy. Dr Steensma highlights how the majority of low-risk MDS patients are treated with hematopoietic growth factors or lenalidomide, although certain patients will respond to immunosupressants and hypomethylating agents. He expresses his hopes for the potential of luspatercept, a recombinant fusion protein, as well as oral hypomethylating agents, the telomerase inhibitor imetelstat and splicing inhibitors.
